惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

J
Java Code Geeks
Martin Fowler
Martin Fowler
MongoDB | Blog
MongoDB | Blog
博客园 - Franky
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
Microsoft Security Blog
Microsoft Security Blog
H
Hackread – Cybersecurity News, Data Breaches, AI and More
博客园_首页
腾讯CDC
D
Docker
The Cloudflare Blog
量子位
爱范儿
爱范儿
L
LangChain Blog
博客园 - 三生石上(FineUI控件)
博客园 - 司徒正美
aimingoo的专栏
aimingoo的专栏
Blog — PlanetScale
Blog — PlanetScale
Jina AI
Jina AI
Apple Machine Learning Research
Apple Machine Learning Research
Hugging Face - Blog
Hugging Face - Blog
博客园 - 聂微东
Vercel News
Vercel News
MyScale Blog
MyScale Blog

Politics - CBSNews.com

Caine warns "we will use force" if Iran does not comply with blockade on Strait of Hormuz House breaks with Trump, voting against ending deportation protections for Haitians Sotomayor apologizes for criticizing Kavanaugh over ICE arrests, in rare public Supreme Court clash 3 killed in latest U.S. strike on alleged drug boat in eastern Pacific, Pentagon says Gabbard sends criminal referrals to DOJ for whistleblower and watchdog who helped launch Trump 4/15: The Takeout with Major Garrett Family speaks out as single mom remains detained for nearly a month: "It doesn't feel right" Treasury secretary says Americans can already see refunds as Trump's tax breaks kick in 4/15: CBS Evening News Billionaires, dark money fuel questions ahead of 2026 midterms DOJ moves to dismiss Jan. 6 convictions against former Proud Boys and Oath Keepers, including seditious conspiracy charges Senate rejects 4th attempt to curb Trump's war powers in Iran Why Jerome Powell — not Trump — will decide when the Federal Reserve chief exits the scene House Democrats file articles of impeachment against Hegseth Controversial surveillance program faces uncertain future ahead of House vote Trump aide Sebastian Gorka signals he's interested in top counterterrorism post Dr. Erica Schwartz emerges as White House's top pick for CDC leader D.C. pipe bomb suspect, Brian Cole Jr., hit with 2 new charges New federal Medicaid rules require 1 month of work. Some states demand more. Latest Eric Swalwell accuser alleges he drugged and raped her Prosecutors from Jeanine Pirro's office tried to access Federal Reserve headquarters, but were turned away A bipartisan duo helped force Reps. Swalwell and Gonzales to resign. They say other House members could be next. 4/14: The Takeout with Major Garrett Fourth U.S. strike on alleged drug boat in days kills 4 in the eastern Pacific House passes aviation safety bill in response to deadly midair collision near D.C. U.S. hosts Israel and Lebanon for first talks in over 30 years Eric Swalwell accuser says, "I'm terrified to speak out" Ex-White House chief of staff Mark Meadows seeks reimbursement from DOJ for legal fees incurred in Trump-related probes 11 races that could determine control of the Senate Appeals court shuts down criminal contempt probe over deportation flights of Venezuelan migrants
FDA will consider easing restrictions on peptides as RFK ...
2026-04-16 · via Politics - CBSNews.com

/ AP

Add CBS News on Google

The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular among wellness influencers, fitness gurus and celebrities.

The meeting announcement Wednesday follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on peptides, which are often pitched as a quick way to build muscle, heal injuries or appear younger. There's little research behind those claims, and most peptides have not been reviewed for safety by the FDA. 

Kennedy has discussed using peptides for his own injuries. And some major supporters of his Make America Healthy Again movement are big proponents of them, including Gary Brecka, a self-described "longevity expert" who sells various peptide formulas through his website.

The FDA said in a federal notice Wednesday it will ask a panel of outside advisers to review seven peptides at a meeting in July, specifically whether they should be added to a list of substances that can be safely produced by pharmacies. In the meantime, the agency said it would soon remove the chemicals from a restrictive list reserved for unapproved, high-risk drugs. The peptides under discussion include some of the most popular among influencers, such as BPC-157, which is marketed to heal injuries and reduce inflammation.

"The Wild West is about to become wilder," said Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest. In an interview, Lurie said allowing peptides on the market without clinical testing poses a "profound threat" to FDA's decades-old system for vetting drugs.

"I don't see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market," he said.

Under President Joe Biden, the FDA added nearly 20 peptides to the federal list of substances that should not be produced by compounding pharmacies — businesses that mix medications that aren't available from drugmakers.

At the time, the FDA's panel of pharmacy advisers voted overwhelmingly that the peptides did not meet the criteria for substances that can be safely compounded. And FDA regulators agreed, saying later that the substances "present significant safety risks," because most have not been extensively tested in humans.

Many of the FDA advisers and internal staff who oversaw those decisions no longer work for the agency. The FDA's pharmacy panel currently has a number of vacancies, which Kennedy could fill before the July meeting.

Kennedy previewed Wednesday's move in an interview with podcast host Joe Rogan. Both men have repeatedly spoken about peptides and claimed to have benefited from their use.

"I'm a big fan of peptides," Kennedy told Rogan. "I've used them myself and with really good effect on a couple of injuries."

Given Kennedy's statements, Lurie said it was doubtful the drugs would receive real scrutiny from FDA.

"Everybody knows the outcome that the secretary wants," Lurie said. "I don't believe for one moment that what's going on here is an honest investigation of whether these products should be compounded."

Scott Brunner of the Alliance for Pharmacy Compounding said the coming meeting will be the start of a "protracted process." Even if the panel votes to make the peptides available, and FDA agrees, the agency will still have to draft and publish rules on the change, he noted.

Peptides are essentially the building blocks of more complex proteins. Inside the human body, peptides trigger hormones needed for growth, metabolism and healing.

In recent years, peptides have become widely known through the blockbuster success of GLP-1 medications, which the FDA has approved for treating obesity and diabetes. Other FDA-approved peptides include insulin for diabetics and hormone-based drugs for several medical conditions.

But many of the peptides promoted online have never been approved, making them technically illegal to market as drugs. Several peptides, such as BPC-157 and TB-500, are banned by international sports authorities as doping substances.

But that has not stopped them from gaining a foothold in the burgeoning marketplace for wellness hacks and alternative remedies.

"I think this is a disaster in the works," said Dr. Eric Topol of Scripps Research Translational Institute, who has studied the issue. "These peptides have no data to support their safety and efficacy."

Meanwhile, some dietary supplement makers have begun mixing peptides into capsules, protein powders and gummies. At a recent FDA meeting, the industry argued for expanding the federal definition of supplements to permit the use of newer ingredients like peptides in their products.

When the FDA added a number of injectable peptides to its list of restricted substances in 2023, it cited safety risks including cancer and liver, kidney and heart problems.

That triggered pushback from wellness entrepreneurs, compounding pharmacies and their allies in Washington.

Last year several members of Congress, including Republican Sen. Tommy Tuberville of Alabama, sent letters to Kennedy asking him to lift limits on peptide production.

Some in the compounding industry argue that FDA's restrictions have given rise to an illicit market of imported chemicals from China and other countries, which are not subject to U.S. drug standards.

Kennedy has echoed those concerns.

"With the gray market you have no idea if you're getting a good product," Kennedy told Rogan. "And a lot of this stuff that we've looked at is just very, very substandard."

In: